

Mesotelioma

Cisplatina + Doxorrubicina

Doxorrubicina: 60mg/m ²	IV	D1
Cisplatina: 60mg/m ²	IV	D1 a cada 21 dias
Ref. (1)		

CAP

Ciclofosfamida: 500mg/m ²	IV	D1
Doxorrubicina: 50mg/m ²	IV	D1
Cisplatina: 80mg/m ²	IV	D1 a cada 21 dias
Ref. (2)		

Gencitabina + Cisplatina

Gencitabina: 1000mg/m ²	IV	D1, D8, D15
Cisplatina: 100mg/m ²	IV	D1 a cada 28 dias
Ref. (3)		

Gencitabina+ Carboplatina

Gencitabina: 1000mg/m ²	IV	D1, D8, D15
Carboplatina: AUC 5	IV	D1 a cada 28 dias
Ref. (4)		

Pemetrexede + Cisplatina

Pemetrexede: 500mg/m ²	IV	D8
Cisplatina: 75mg/m ²	IV	D1, D8 a cada 21 dias
Ref. (5)		

Pemetrexede

Pemetrexede: 500mg/m² IV em 10 min D1
a cada 21 dias
Ref. (6)

Vinorelbina

Vinorelbina: 30mg/m² IV D1 semanalmente durante 6 ou 12 semanas (com intervalo de 2 semanas entre a 6^a e 7^a dose).

Ref. (7)

Pemetrexede + Carboplatina

Pemetrexede: 500mg/m² IV D1

Carboplatina: AUC de 5 IV D1

a cada 21 dias

Ref. (8)

Cisplatina e Raltitrexede

Cisplatina : 80 mg/m² IV D1

Raltitrexede: 3 mg/m² IV D1 a cada 21 dias

Ref. (9)

Raltitrexede

Raltitrexede: 3 mg/m² IV D1 a cada 21 dias

Ref. (10)

1. Ardizzoni, A., *et al.* Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. *Cancer*, 1991. 67(12): p. 2984-7.
2. Shin, D.M., *et al.* Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. *Cancer*, 1995. 76(11): p. 2230-6.
3. Nowak, A.K., *et al.* A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. *Br J Cancer*, 2002. 87(5): p. 491-6.
4. Favaretto, A.G., *et al.* Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. *Cancer*, 2003. 97(11): p. 2791-7.

5. Vogelzang, N.J., *et al.* Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol*, 2003. 21(14): p. 2636-44.
6. Taylor, P *et al.* Single-Agent Pemetrexed for Chemonaive and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. *Journal of Thoracic Oncology*, 2008;3:764-771.
7. Stebbing J, *et al.* The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. *Lung Cancer* 2009; 63:94-7.
8. Ceresoli GL, *et al.* Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. *J Clin Oncol* 2006; 24:1443-1448.
9. van Meerbeeck JP, *et al.* Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005;23:6881-9.
10. Baas P, *et al.* The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: an EORTC phase II study (08992). *Eur J Cancer* 2003;39:353-7.